Cambridge Investment Research Advisors Inc. increased its holdings in VBI Vaccines Inc (NASDAQ:VBIV) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,368,021 shares of the biopharmaceutical company’s stock after purchasing an additional 66,548 shares during the period. Cambridge Investment Research Advisors Inc. owned 2.12% of VBI Vaccines worth $3,311,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in VBIV. Menora Mivtachim Holdings LTD. grew its position in shares of VBI Vaccines by 27.4% in the second quarter. Menora Mivtachim Holdings LTD. now owns 3,459,868 shares of the biopharmaceutical company’s stock valued at $9,515,000 after purchasing an additional 744,706 shares during the period. Millennium Management LLC grew its position in VBI Vaccines by 118.7% during the second quarter. Millennium Management LLC now owns 531,117 shares of the biopharmaceutical company’s stock valued at $1,461,000 after acquiring an additional 288,214 shares during the period. General American Investors Co. Inc. grew its position in VBI Vaccines by 44.1% during the second quarter. General American Investors Co. Inc. now owns 864,464 shares of the biopharmaceutical company’s stock valued at $2,377,000 after acquiring an additional 264,464 shares during the period. Jane Street Group LLC purchased a new stake in VBI Vaccines during the second quarter valued at about $331,000. Finally, Paloma Partners Management Co purchased a new stake in VBI Vaccines during the second quarter valued at about $254,000. 48.11% of the stock is owned by institutional investors and hedge funds.

VBIV stock opened at $1.91 on Wednesday. VBI Vaccines Inc has a 12-month low of $1.64 and a 12-month high of $5.10. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14.

VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). VBI Vaccines had a negative net margin of 6,345.29% and a negative return on equity of 53.07%. The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.24 million. Equities research analysts forecast that VBI Vaccines Inc will post -1 EPS for the current fiscal year.

A number of equities research analysts have issued reports on VBIV shares. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Thursday, July 26th. BMO Capital Markets lowered their price target on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, July 27th. Finally, ValuEngine raised VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. VBI Vaccines has an average rating of “Hold” and an average target price of $8.63.

COPYRIGHT VIOLATION NOTICE: “VBI Vaccines Inc (VBIV) Stake Raised by Cambridge Investment Research Advisors Inc.” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/14/vbi-vaccines-inc-vbiv-stake-raised-by-cambridge-investment-research-advisors-inc.html.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Read More: Float

Institutional Ownership by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.